The Essential Role of Assay Validation in Cell Therapy
Development
Cell therapy products are designed to treat life-threatening conditions where no alternative cure exists. To accelerate their availability, regulatory agencies have introduced expedited approval pathways. However, developers of cell therapies still face significant challenges in chemistry, manufacturing, and controls (CMC), particularly in analytical method development and validation.
Cell therapy products have unique critical quality attributes (CQAs) that may not be fully defined at early development stages. This makes the validation of assays crucial to ensure the reliability of analytical data. A robust analytical framework is key to monitoring CQAs effectively, ensuring patient safety, and supporting long-term commercial success.
PHASE APPROPRIATE APPROACH TO METHOD VALIDATION
1. Preclinical Development: Establishing the Analytical Target Profile (ATP)
The analytical journey begins in preclinical development with the establishment of an Analytical Target Profile (ATP), ensuring alignment with the Quality Target Product Profile (QTPP). This phase focuses on identifying potential Critical Quality Attributes (pCQAs) that influence product safety, efficacy, and consistency, such as identity, potency, purity, and viability.
Early assay development efforts evaluate whether existing platform methods can be adapted or if new methods need to be developed. A risk-based approach is employed to determine critical assay parameters, leveraging techniques like Design-of-Experiments (DoE) to optimize method conditions and establish robustness. This foundational work ensures that the selected analytical methods can reliably support subsequent clinical development.
2. Early Clinical Development: Method Qualification
Upon submission of the Investigational Medicinal Product Dossier (IMPD), the focus shifts to method qualification. At this stage, analytical methods undergo preliminary evaluation to confirm their suitability for their intended purpose. While full validation is not yet required, method qualification ensures adequate specificity, precision, and reliability in measuring critical parameters.
At this stage, full GMP implementation is not yet required. However, at Cell-Easy, we proactively apply GMP principles early in the process to uphold the highest standards of quality and reliability. This approach not only aligns with anticipated regulatory expectations but also facilitates a smoother transition into later clinical phases. Partnering with a CDMO offers a strategic advantage, as our laboratories use validated equipment and methods, drawing on extensive experience from previous projects. This proactive strategy helps mitigate risks, ensures data integrity, and accelerates development timelines.
3. Late-Stage Development & Method Validation
As the product progresses into clinical trials and enters the Process Performance Qualification (PPQ) stage, method validation becomes a key element of the development process, following regulatory standards such as ICH Q2(R2). The validation process confirms that critical performance characteristics—accuracy, precision, specificity, detection limit, quantitation limit, linearity, and range—are well established and compliant with regulatory expectations. While GMP-grade methods may not have been a requirement during earlier stages, they are mandatory during this phase.
4. Commercial Manufacturing
Once a cell therapy product receives marketing authorization, the final validated analytical methods are included in the Biological License Application (BLA) or Marketing Authorization Application (MAA). To ensure long-term assay reliability, continued performance monitoring is implemented throughout the product’s lifecycle.
THE ANALYTICAL METHOD JOURNEY: FROM DEVELOPMENT TO VALIDATION
The development and validation of analytical methods follow an iterative and collaborative approach involving multiple teams. It begins with R&D developing methods to align with product characteristics and regulatory expectations. Quality Control (QC) is often involved to assess feasibility and ensure a smooth transfer. Once the method reaches a sufficient level of refinement, it undergoes method qualification to verify accuracy and reproducibility under controlled conditions. Next, the Quality Assurance (QA) team oversees the validation process before the method is officially adopted for GMP manufacturing. Upon successful validation, the method becomes the established standard, ensuring the safety, quality, and consistency of GMP-manufactured products.
Example of a Method Validation at Cell Easy
In cell therapy production, precision is everything. A small error in cell counting can compromise both product quality and batch consistency. As manufacturing scales, relying on manual counting simply isn’t enough. It’s time to automate—but that transition isn’t without its challenges. The real test lies in fine-tuning the automated system to match, or even exceed, the accuracy of manual methods. Method validation ensures that cell counting is optimal to support every phase of production, safeguarding product integrity at every turn.
Cell-Easy’s development process follows a structured chronology to ensure analytical method reliability. Establishing an automated system requires meticulous selection and fine-tuning of parameters to accurately differentiate cells of interest from sample debris and dead cells. Optimizing factors such as brightness, contrast, cell size, and circularity is an iterative process, requiring multiple adjustments and verifications to ensure only relevant cells are counted. The Limit of Quantification (LOQ) is also established to define the threshold of reliable accuracy.
Once sufficiently optimized, the system is transferred to the Quality Control (QC) team for qualification. The system is tested under controlled conditions, comparing results with the manual “gold standard” to verify accuracy and reproducibility Additionally, the system must be reassessed for each cell type to ensure consistent performance and reliability across different applications.
Following qualification, the method undergoes validation, rigorously tested under conditions simulating actual production environments, identifying potential weaknesses. Only once these validation tests are passed does the method become the official reference standard for GMP manufacturing.
REGULATORY LANDSCAPE – SOME GUIDELINES
Understanding regulatory guidelines is essential for ensuring compliance and streamlining cell therapy development. Regulatory agencies such as the FDA and EMA outline distinct yet complementary expectations that evolve throughout clinical development. Below are key regulatory expectations for method qualification and validation across different stages of development.
FDA Expectations
The FDA’s CMC guidance indicates that full analytical method validation is not required for initial IND submissions (Phase I) in cell therapy. However, test methods must be scientifically rigorous, well-controlled, and capable of ensuring specificity, sensitivity, and reproducibility. The FDA encourages the use of compendial methods where applicable and mandates qualification of safety-related assays before clinical trials. Additionally, assays detecting potential contaminants (e.g., residual cytokines, adventitious agents) should meet FDA sensitivity standards early in development.
EMA Expectations
The EMA aligns with the FDA on many principles but places greater emphasis on safety assay validation. According to EU GMP guidelines for ATMPs:
- Early-stage trials: Sterility and microbial testing must be validated, along with assays critical to patient safety (e.g., replication-competent virus detection for viral vector-based cell therapies).
- Throughout development: Full validation is not required, but methods must reliably assess critical quality attributes such as cell viability, impurity detection, and functional characterization. Potency assays should be validated before pivotal trials.
- Pivotal trials: Analytical methods for batch release and stability testing must be fully validated.
THE ANALYTICAL METHOD JOURNEY: FROM DEVELOPMENT TO VALIDATION
As cell therapy products progress through clinical development, the analytical methods used to assess their quality must evolve in parallel. The life cycle of these methods mirrors the product life cycle, with adjustments made as new insights and data are gained. By applying a risk-based approach, analytical methods can be tailored to meet the specific needs of each stage, ensuring they remain fit for purpose—from early feasibility studies to commercial manufacturing. Below are the key steps in the analytical method life cycle.
ASSAY VALIDATION: PARTNERING WITH CELL-EASY
Partnering with a CDMO for assay validation can be a strategic move to streamline your development process. By tapping into their expertise and infrastructure, you gain access to efficient methods and technologies that can help ensure your assays meet regulatory standards. This collaboration allows you to optimize your methods while managing risks and improving data integrity. The right CDMO partnership can support your timeline, but it’s essential to carefully assess their capabilities to ensure they align with your specific needs, ultimately helping you navigate the regulatory landscape more effectively and bringing your product to market faster. For any assistance or more information, feel free to contact us—we’re here to help guide you through every step of the process.
Explore our services at www.cell-easy.com or contact us at info@cell-easy.com